Generics Bulletin Originals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

What’s Next? Five Things To Look Out For In May
This month, Eli Lilly’s Alimta blockbuster will lose patent protection in the US, while Teva – which will also publish its Q1 financial results – will see Bristol Myers Squibb begin its appeal process against a key UK ruling involving the originator’s Eliquis (apixaban) anticoagulant.

What’s Next? Five Things To Look Out For In April
In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.

What’s Next? Five Things To Look Out For In March
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.

What’s Next? Five Things To Look Out For In February
In February, key launches from Accord and Eagle are set to go ahead, while Viatris will host its delayed investor day and industry will meet in-person in Florida for the US Association for Accessible Medicines’ Access! event.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
.jpg?rev=8da28dd353b74773b604dcb7e9ada103&w=350&hash=F97AB6D6028EB034DBAE819A86428EDA)
Samsung Bioepis ‘Setting A High Bar’ For Next Wave Of Biosimilars
In the wake of parent company Samsung Biologics completing its full acquisition of Samsung Bioepis, the Korea-based biosimilars player has told Generics Bulletin that it will be a “more robust company,” as it applies more rigorous standards to replenishing its pipeline of biosimilar candidates.

Biosimilars Forum Calls For Further Action On Biden’s Competition Order
Generics Bulletin sits down with Biosimilars Forum executive director Julie Reed to discuss preparing the HHS for Humira biosimilars, what more the agency could do for the industry and the Forum’s priorities over the next year.

Oral Humira Biosimilar Could Be A Game-Changer, Says Rani CEO
Oral delivery of biosimilars could bring significant benefits for patients as well as offering a key differentiating factor for competing developers, especially in the US adalimumab arena, Rani Therapeutics CEO Talat Imran tells Generics Bulletin.

Stampa Urges Investment In European Manufacturing
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Solifenacin Surges As UK Sees Huge Price Rises In April
Multiple different generics saw triple-digit-percentage price rises that led UK averages to as much as quadruple in April 2022, according to the latest figures from WaveData. Solifenacin and ibandronic acid led the month’s steepest increases.

UK Pramipexole Prices Plummet In March
Multiple presentations of pramipexole modified-release tablets saw their average UK trade prices nosedive in March, according to the latest figures from market researcher WaveData, which also revealed the reason for the dramatic declines.

Trio Of Generics See UK Prices Double In February
Three different generics saw their average UK trade price more than double in February 2022, according to the latest figures from WaveData, with losartan/hydrochlorothiazide, ascorbic acid and amoxicillin leading the month’s biggest rises.

UK Kicks Off 2022 With Celecoxib And Rizatriptan Rises
UK average trade prices for certain presentations of celecoxib and rizatriptan trebled and even quadrupled in the first month of 2022, according to the latest figures from WaveData.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.